Abstracts Archive - Page 179 of 2607 - ACR Meeting Abstracts

Abstract Number: 1323 • ACR Convergence 2025
Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
Tatiana Lisitsyna¹, Anton Abramkin², Dmitry Veltishchev³, Sofia Kuzkina⁴, Anastasia Borisova², Vasily Ignatiev⁵, Mikhail Samsonov⁶ and Eugeny Nasonov², ¹Thromboinflammation Laboratory of the Department of Systemic Rheumatic Diseases V.A.Nasonova Research Institute of Rheumatology, Moskva, Russia, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴R-Pharm, Moscow, Russia, ⁵"R-Pharm", JSC, Moscow, Russia, ⁶RPharm, Brussels, Belgium
Background/Purpose: Interleukin (IL)-6 plays an important role in the pathogenesis of depression in rheumatoid arthritis (RA) patients. IL-6 inhibitors used to treat patients with RA…
Abstract Number: 1346 • ACR Convergence 2025
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
YU Chen¹, Chien-Sheng Wu², Jacob Shujui Hsu³ and Pei-Lung Chen⁴, ¹Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., New Taipei City, Taiwan (Republic of China), ²Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C., New Taipei city, Taiwan (Republic of China), ³Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei city, Taiwan (Republic of China), ⁴Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan (Republic of China)
Background/Purpose: Multiple Single-Nucleotide Polymorphisms (SNPs), including those in the methotrexate and azathioprine metabolic pathways, are associated with poor response to conventional disease-modifying anti-rheumatic drugs (cDMARDs)…
Abstract Number: 1335 • ACR Convergence 2025
Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis
Jesús Loarce¹, Alonso Sebastián González Montes², SONIA JIMENEZ BARRIOS³, Mauro Ferre-Sanfrancisco⁴, Verónica García García⁵ and Javier Bachiller⁶, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Ramón y Cajal university hospital, Madrid, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, Madrid, Madrid, Spain, ⁵Ramón y Cajal University Hospital, MADRID, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA). Although early diagnosis and screening of ILD in RA patients…
Abstract Number: 1265 • ACR Convergence 2025
Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations
Emily Gutowski¹, Joshua Novack², Allyson Covello², Philip Carlucci³, Scott Goldberg¹, Mary Guan⁴, Marcus Hines², Elliot Philips², Michael Pillinger⁵ and Sara Stream⁶, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²New York University Grossman School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴NYU Grossman SOM, Brooklyn, NY, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶New York University Grossman School of Medicine, Great Neck, NY
Background/Purpose: Patients with rheumatic diseases face complex and chronic diagnoses that require close monitoring and frequent communication with their providers. Given increasing challenges to in-person…
Abstract Number: 1341 • ACR Convergence 2025
Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Saskia Truijen¹, Annelies Boonen¹, Sofia Ramiro² and Marloes van Onna¹, ¹Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) may accelerate age-related functional decline compared to the general population. This study aimed to examine whether four performance measures of physical…
Abstract Number: 1252 • ACR Convergence 2025
Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Melissa Mannion¹, Bryce Thornton¹, Bella Mehta², Ronan O'Beirne¹, Emily Smitherman¹, Livie Timmerman³, Shilpa Venkatachalam⁴, Jeffrey Curtis¹ and John Osborne¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Global Healthy Living Foundation, New York, NY
Background/Purpose: Identifying informational needs of individuals with inflammatory arthritis is critical to enhancing communication and supporting shared decision making between patients, caregivers, and providers. However,…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1351 • ACR Convergence 2025
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York
Background/Purpose: Previous studies suggest that glucocorticoids are associated with worse survival in patients receiving immune checkpoint inhibitors (ICI). This is an important issue for Rheumatoid…
Abstract Number: 1230 • ACR Convergence 2025
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Gillian Fennell¹, Sarah Tilley², Sayali Dhamne³, Robert Edwards⁴, Mary Gheller³, Angelo Demalia³, Margaret Clancy³, Michael LaValley⁵, Emelia J Benjamin³ and Tuhina Neogi⁶, ¹Boston University Medical, Boston, MA, ²Boston University School of Medicine, Somerville, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Over a third of older Americans experience chronic pain, typically occupying multiple musculoskeletal body sites. While number of pain sites (NPS) is often touted…
Abstract Number: 1263 • ACR Convergence 2025
Health Literacy diversity among rheumatology patients: insights from a tertiary rheumatology centre
Cristina Calomarde-Gomez¹, Mrinalini Dey², Chris Wincup³, María Alonso de Francisco⁴, Christina Cheng⁵, Richard Osborne⁵ and Elena Nikiphorou⁶, ¹Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, ⁵La Trobe University, Melbourne, Victoria, Australia, ⁶King's College London, London, United Kingdom
Background/Purpose: Health literacy is a potential social determinant of health, fundamental to patient engagement, clinical communication, and long-term outcomes of disease. Understanding health literacy at…
Abstract Number: 1156 • ACR Convergence 2025
Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort
elena Joerns¹, Sara Achenbach¹, Cynthia Crowson², eva carmona¹, Robert Vassallo³, John Joerns¹, Vanessa Kronzer³, John Davis³ and Elena myasoedova³, ¹Mayo Clinic, Rochester, ²Mayo Clinic, Stewartvillle, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial lung disease (ILD) with features of autoimmunity, yet patients do not fulfill criteria…
Abstract Number: 1366 • ACR Convergence 2025
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Rémi Marty¹, Baran Ufuktepe², Nicola Tilt³, Flore Decuypere⁴, Angela Blake³, Sandeep Kiri³ and Mohammed Soomro³, ¹UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, ²UCB Pharma Istanbul, Turkey, istanbul, Turkey, ³UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, ⁴UCB Pharma Brussels, Belgium, Brussels, Belgium
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].